US FDA delays NPS short bowel drug by 3 months
This article was originally published in Scrip
Executive Summary
Investors took the news in stride about the US FDA's three-month delay on its decision for NPS Pharmaceuticals’ short bowel syndrome (SBS) drug Gattex (teduglutide) – with shares of the firm actually getting a 3.2% boost during trading on 13 August.